ORBi: Detailled Reference

Article (Scientific journals)

Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?

Reenaers, Catherine; Belaiche, Jacques; Louis, Edouard

2010 • In Inflammatory Bowel Diseases, 16 (8), p. 1271-2

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/84550

DOI
10.1002/ibd.21162

PubMed
20027649

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2010-Schould patients under long-term anti-TNF...-IBD-traité OCR PostPA.pdf

Author postprint (20.57 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Adult; Antibodies, Monoclonal/adverse effects/therapeutic use; Azathioprine/therapeutic use; Colitis, Ulcerative/drug therapy; Corticosterone/therapeutic use; Crohn Disease/drug therapy; Female; Gastrointestinal Agents/adverse effects/therapeutic use; Humans; Latent Tuberculosis/immunology/radiography; Male; Methotrexate/therapeutic use; Tuberculosis, Pulmonary/immunology/radiography; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Reenaers, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Belaiche, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

English

Title :

Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?

Publication date :

2010

Journal title :

Inflammatory Bowel Diseases

ISSN :

1078-0998

eISSN :

1536-4844

Publisher :

Lippincott Williams & Wilkins, Hagerstown, United States - Maryland

Volume :

16

Issue :

8

Pages :

1271-2

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 11 February 2011

Statistics

Number of views

125 (5 by ULiège)

Number of downloads

276 (8 by ULiège)

More statistics

Scopus citations^®

6

Scopus citations^®
without self-citations

6

OpenCitations

3

OpenAlex citations

6

Bibliography

Maini SR. Infliximab treatment of rheumatoid arthritis. Rheum Dis Clinics N Am. 2004;30:329-347.
Keane J, Geeshon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious disease associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-1265. (Pubitemid 38608568)
Salmon-Ceron D. Recommendations for the prevention and management of in patients taking infliximab. Ann Med Interne (Paris). 2002;153:429-431. (Pubitemid 36033716)
Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS. 2002;16:2285-2293. (Pubitemid 35449014)
Tam LS, Li EK, Wong SM, et al. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31:296-300. (Pubitemid 35252543)
Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350:2060-2067.
Radhakrishna S, Frieden TR, Subramani R. Association of initial tuberculin sensitivity, age and sex with the incidence of tuberculosis in south India: a 15-year year follow-up. Int J Tuberc Lung Dis. 2003;7:1083-1091.
Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2:561-572.
Jacobs M, Samarina A, Grivennikov S, et al. Reactivation of tuberculosis by tumor necrosis factor neutralization. Eur Cytokine Netw. 2007;18:5-13. (Pubitemid 46848053)

Similar publications